{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:36:18Z","timestamp":1790638578425,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,14]]},"DOI":"10.7759\/cureus.105206","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:39:46Z","timestamp":1773477586000},"source":"Crossref","is-referenced-by-count":1,"title":["Mesenchymal Stem Cell Therapy in Parkinson\u2019s Disease: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Afra A","family":"Al Darmaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rokia","family":"Malahifci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naya I","family":"Al Mikhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifan","family":"Khanday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina S","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia LV","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015, 386:896-912. 10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe W","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, et al.. Parkinson disease. Nat Rev Dis Primers. 2017, 3:17013. 10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications","volume":"5","author":"Olanow CW","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5:677-87. 10.1016\/S1474-4422(06)70521-X","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?","volume":"8","author":"Hirsch EC","year":"2009","unstructured":"Hirsch EC, Hunot S. Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-97. 10.1016\/S1474-4422(09)70062-6","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey MG","year":"2010","unstructured":"Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010, 37:510-8. 10.1016\/j.nbd.2009.11.004","journal-title":"Neurobiol Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson's disease","volume":"26","author":"Schapira AH","year":"2011","unstructured":"Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord. 2011, 26:1049-55. 10.1002\/mds.23732","journal-title":"Mov Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0051","article-title":"Mesenchymal stem cells: time to change the name!","volume":"6","author":"Caplan AI","year":"2017","unstructured":"Caplan AI. Mesenchymal stem cells: time to change the name!. Stem Cells Transl Med. 2017, 6:1445-51. 10.1002\/sctm.17-0051","journal-title":"Stem Cells Transl Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3584-0_7","article-title":"Paracrine mechanisms of mesenchymal stem cells in tissue repair","volume":"1416","author":"Gnecchi M","year":"2016","unstructured":"Gnecchi M, Danieli P, Malpasso G, Ciuffreda MC. Paracrine mechanisms of mesenchymal stem cells in tissue repair. Methods Mol Biol. 2016, 1416:123-46. 10.1007\/978-1-4939-3584-0_7","journal-title":"Methods Mol Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3727\/096368915X689622","article-title":"Clinical trials with mesenchymal stem cells: an update","volume":"25","author":"Squillaro T","year":"2016","unstructured":"Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016, 25:829-48. 10.3727\/096368915X689622","journal-title":"Cell Transplant"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-03050-4","article-title":"The potential use of mesenchymal stem cells and their exosomes in Parkinson's disease treatment","volume":"13","author":"Heris RM","year":"2022","unstructured":"Heris RM, Shirvaliloo M, Abbaspour-Aghdam S, et al.. The potential use of mesenchymal stem cells and their exosomes in Parkinson's disease treatment. Stem Cell Res Ther. 2022, 13:371. 10.1186\/s13287-022-03050-4","journal-title":"Stem Cell Res Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici M","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, et al.. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8:315-7. 10.1080\/14653240600855905","journal-title":"Cytotherapy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04240-9","article-title":"Clinical potential and current progress of mesenchymal stem cells for Parkinson's disease: a systematic review","volume":"41","author":"Chen Y","year":"2020","unstructured":"Chen Y, Shen J, Ke K, Gu X. Clinical potential and current progress of mesenchymal stem cells for Parkinson's disease: a systematic review. Neurol Sci. 2020, 41:1051-61. 10.1007\/s10072-020-04240-9","journal-title":"Neurol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28582","article-title":"Allogeneic bone marrow-derived mesenchymal stem cell safety in idiopathic Parkinson's disease","volume":"36","author":"Schiess M","year":"2021","unstructured":"Schiess M, Suescun J, Doursout MF, et al.. Allogeneic bone marrow-derived mesenchymal stem cell safety in idiopathic Parkinson's disease. Mov Disord. 2021, 36:1825-34. 10.1002\/mds.28582","journal-title":"Mov Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.950715","article-title":"Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: a systematic review","volume":"13","author":"Liu SF","year":"2022","unstructured":"Liu SF, Li LY, Zhuang JL, et al.. Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: a systematic review. Front Neurol. 2022, 13:950715. 10.3389\/fneur.2022.950715","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli A","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008, 8:726-36. 10.1038\/nri2395","journal-title":"Nat Rev Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000349","article-title":"How strong is the evidence that Parkinson's disease is a prion disorder?","volume":"29","author":"Brundin P","year":"2016","unstructured":"Brundin P, Ma J, Kordower JH. How strong is the evidence that Parkinson's disease is a prion disorder?. Curr Opin Neurol. 2016, 29:459-66. 10.1097\/WCO.0000000000000349","journal-title":"Curr Opin Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.09.004","article-title":"Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program","volume":"27","author":"Vij R","year":"2025","unstructured":"Vij R, Kim H, Park H, Cheng T, Lotfi D, Chang D. Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program. Cytotherapy. 2025, 27:181-7. 10.1016\/j.jcyt.2024.09.004","journal-title":"Cytotherapy"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/mds.70028","article-title":"Allogeneic bone marrow-derived mesenchymal stem cells for Parkinson's disease: a randomized trial","volume":"40","author":"Schiess MC","year":"2025","unstructured":"Schiess MC, Suescun J, Martinez-Lemus JD, et al.. Allogeneic bone marrow-derived mesenchymal stem cells for Parkinson's disease: a randomized trial. Mov Disord. 2025, 40:2688-99. 10.1002\/mds.70028","journal-title":"Mov Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau J","year":"2018","unstructured":"Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018, 22:824-33. 10.1016\/j.stem.2018.05.004","journal-title":"Cell Stem Cell"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1129","article-title":"Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth","volume":"30","author":"Xin H","year":"2012","unstructured":"Xin H, Li Y, Buller B, et al.. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 2012, 30:1556-64. 10.1002\/stem.1129","journal-title":"Stem Cells"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2009.07.006","article-title":"Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease","volume":"155","author":"Venkataramana NK","year":"2010","unstructured":"Venkataramana NK, Kumar SK, Balaraju S, et al.. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res. 2010, 155:62-70. 10.1016\/j.trsl.2009.07.006","journal-title":"Transl Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/14653240802021330","article-title":"Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease","volume":"10","author":"Levy YS","year":"2008","unstructured":"Levy YS, Bahat-Stroomza M, Barzilay R, et al.. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy. 2008, 10:340-52. 10.1080\/14653240802021330","journal-title":"Cytotherapy"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2025.10.020","article-title":"Mesenchymal stem cells in neurological disorders: insights from clinical trials","volume":"30","author":"Ara\u00fajo B","year":"2025","unstructured":"Ara\u00fajo B, Serrenho I, Valente da Silva A, Marceta BM, Baltazar G. Mesenchymal stem cells in neurological disorders: insights from clinical trials. Regen Ther. 2025, 30:1024-35. 10.1016\/j.reth.2025.10.020","journal-title":"Regen Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu MM","year":"2012","unstructured":"Lalu MM, McIntyre L, Pugliese C, et al.. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012, 7:e47559. 10.1371\/journal.pone.0047559","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21894","article-title":"Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions","volume":"23","author":"Goetz CG","year":"2008","unstructured":"Goetz CG, Wuu J, McDermott MP, et al.. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008, 23:690-9. 10.1002\/mds.21894","journal-title":"Mov Disord"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0282","article-title":"Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions","volume":"7","author":"Bauer G","year":"2018","unstructured":"Bauer G, Elsallab M, Abou-El-Enein M. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med. 2018, 7:676-85. 10.1002\/sctm.17-0282","journal-title":"Stem Cells Transl Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X20666220327212414","article-title":"Mechanism of mesenchymal stem cells as a multitarget disease-modifying therapy for Parkinson's disease","volume":"21","author":"Unnisa A","year":"2023","unstructured":"Unnisa A, Dua K, Kamal MA. Mechanism of mesenchymal stem cells as a multitarget disease-modifying therapy for Parkinson's disease. Curr Neuropharmacol. 2023, 21:988-1000. 10.2174\/1570159X20666220327212414","journal-title":"Curr Neuropharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/472268-mesenchymal-stem-cell-therapy-in-parkinsons-disease-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T08:39:47Z","timestamp":1773477587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/472268-mesenchymal-stem-cell-therapy-in-parkinsons-disease-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.105206","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,14]]}}}